Biotalys and Novonesis unveiled a comprehensive, long-term collaboration agreement. This partnership encompasses the production, global supply, and certain commercialization rights of EVOCA NG, slated to be Biotalys' inaugural margin-generating biofungicide. Biotalys and Novonesis are completing the manufacturing process development phase for EVOCA NG, which includes an investment by Novonesis to facilitate the scale up in production capacity to support global commercialization.

The companies will also be commercial partners in the distribution and sale of EVOCA NG for select crops outside of the United States. Biotalys will receive a royalty on Novonesis' net sales of EVOCA NG for all covered territories. The agreed royalty percentage is a premium for the sector reflecting the unique of the AGROBODY technology for sustainable crop protection.

The efficacy of its new mode of action has been confirmed through multi-year field trials, and through the granting of a separate FRAC-code for EVOCA. In addition, the companies will explore future collaborations involving Biotalys' promising AGROBODY technology platform, including potential combinations with Novonesis' biocontrol technology.